Clinical trials: Caffeine-Related Disorders
Healthy Volunteers
Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine
This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose of caffeine and the effects that PBT2 has on the metabolism of caffeine in healthy volunteers.
- Trial name
- NCT02109497
- Testing
- PBT2
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Prana Biotechnology Limited
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.
- Trial name
- NCT03970798
- Testing
- Midazolam, Caffeine, Rosuvastatin
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Healthy Volunteer
Determine the Effect of Multiple Doses of AZD7325, CYP Study
To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine [3-desmethyl] metabolite).
- Trial name
- CYP (NCT00790114)
- Testing
- AZD7325, Midazolam, Caffeine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca